HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has consistently positioned technology and clinical infrastructure at the core of its operating model. The platform integrates digital intake, electronic medical records (EMR), prescription workflows and fulfillment into a single end-to-end system, allowing licensed providers to deliver personalized care at scale. This infrastructure supports asynchronous consultations, ongoing provider follow-ups and continuous data capture, enabling treatment plans to be adjusted over time based on patient needs rather than one-time encounters.

During 2025, Hims & Hers further deepened this foundation through targeted investments in data and AI. Leadership additions in technology were paired with expanded efforts to build AI-enabled tools that enhance clinical decision-making, improve routing of patients to appropriate providers, and support more personalized treatment pathways. The platform increasingly uses accumulated clinical and behavioral data to connect diagnostics, prescriptions and care delivery more seamlessly.

Recent product launches reinforce this strategy. The introduction of Labs adds longitudinal diagnostic data — such as biomarker testing — directly into the care experience, strengthening the feedback loop between data, providers and treatment decisions. Similarly, expansions into hormone health, weight management and international markets rely on the same core infrastructure, demonstrating how Hims & Hers is leveraging its integrated technology and clinical systems to scale new specialties while maintaining a consistent, data-driven care model.

TDOC & LFMD’s Integrated Platforms Scaling Clinical Reach

Teladoc Health, Inc. TDOC positions technology and data-driven clinical infrastructure as central to its virtual-care ecosystem. TDOC integrates EMRs, clinician workflows and remote monitoring across its Integrated Care and BetterHelp offerings. Teladoc Health continues to advance AI-enabled capabilities, most recently expanding its Clarity platform to include workplace safety monitoring using real-time video and audio analytics. This expansion reflects how Teladoc Health continues to embed AI-driven monitoring and analytics into hospital and health system workflows to support clinical operations beyond traditional virtual visits.

LifeMD, Inc. LFMD emphasizes deep technology integration as the backbone of its virtual-care model. LFMD operates a proprietary platform that tightly connects EMR, nationwide provider access, diagnostics and pharmacy fulfillment into a single workflow. LifeMD strengthened this infrastructure by launching a state-of-the-art affiliated pharmacy and expanding compounding capabilities. LifeMD also integrated manufacturer partnerships to streamline access to branded GLP-1 therapies. LFMD further reinforced this platform by fully divesting WorkSimpli, positioning LifeMD as a pure-play virtual care and pharmacy company focused on scaling its integrated clinical and technology infrastructure.

HIMS’ Price Performance, Valuation and Estimates

Shares of Hims & Hers have gained 41.1% over the past year, outperforming the industry’s rise of 2.7%.

HIMS’ forward 12-month P/S of 2.8X is lower than the industry’s average of 4.6X, but is higher than its three-year median of 2.6X. It carries a Value Score of D.

The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.

Hims & Hers currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research